In The Light Of Recent Studies In Metastatic Colorectal Cancer
Adding the drug cetuximab to neoadjuvant chemotherapy can shrink tumors and boost
the odds of successful surgery in colorectal cancer patients with inoperable metastatic liver lesions, new research suggests.Tumors spread to other parts of the body in more than half of patients with colorectal cancer.
Most commonly, the cancer spreads to the liver. Removing the tumors in
the liver can cure patients, but about 80 percent have inoperable
disease and a poor prognosis when they see doctors, the researchers
explain in the Nov. 24 online edition of The Lancet Oncology.
Previous research suggests that neoadjuvant treatment with irinotecan-
or oxaliplatin-based chemotherapy can make surgery more likely to
succeed. The new study aimed to see if addition of the drug cetuximab,
also known as Erbitux, would help patients even more.
The study authors, Gunnar Folprecht, from University Hospital Carl
Gustav Carus in Dresden, Germany, and colleagues from Germany and
Austria found that treatment with cetuximab boosted the proportion of
tumors that could be treated with surgery. The treatment, in general,
didnt have serious side effects.
Our data suggest that treatment with cetuximab and chemotherapy
results in high confirmed tumor response rates leading to increased
respectability, Folprecht and colleagues wrote. In the light of
recent studies in metastatic colorectal cancer, the value of further Anti liver cancer treatment intensification will be investigated.
Such as:
Share:
Description: D-Glactosamine Hydrochloride
Synonyms: 2-Amino-2-Deoxy-D-Galactose Hydrochloride; D-Galactosamine Hydrochloride
CAS No.: 1772-03-8
Assay: 98%
Appearance: White powder
Molecular: C6H13NO5HCl
Application: Anti-liver cancer as Pharmaceutical Intermediates
from:timepharm|Pharmaceutical Intermediates
by: wenjun